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ABSTRACT
Objectives: To analyse the relation between selective
serotonin reuptake inhibitor (SSRI) use and major
congenital malformations, with focus on
malformations of the heart.
Design: Register-based retrospective nationwide
cohort study, using the Danish Medical Birth Registry.
Setting: Denmark.
Participants: Pregnant women in Denmark between
1997 and 2009 and their offspring.
Primary outcome measures: For each SSRI, ORs
for major congenital malformations were estimated
using multivariable logistic regression models for
women exposed to an SSRI during the ﬁrst trimester
and for women with paused exposure during
pregnancy.
Results: The authors identiﬁed 848786 pregnancies;
4183 were exposed to an SSRI throughout the ﬁrst
trimester and 806 pregnancies paused exposure
during pregnancy. Risks of congenital malformations
of the heart were similar for pregnancies exposed to an
SSRI throughout the ﬁrst trimester, adjusted OR 2.01
(95% CI 1.60 to 2.53), and for pregnancies with
paused SSRI treatment during pregnancy, adjusted OR
1.85 (95% CI 1.07 to 3.20), p value for difference:
0.94. The authors found similar increased risks of
speciﬁc congenital malformations of the heart for the
individual SSRIs. Furthermore, the authors found no
association with dosage.
Conclusions: The apparent association between SSRI
use and congenital malformations of the heart may be
confounded by indications. The moderate absolute risk
increase combined with uncertainty for causality still
requires the risk versus beneﬁt to be evaluated in each
individual case.
INTRODUCTION
Depression is common during pregnancy
and up to 15% of pregnant women suffer
from depression or depressive symptoms.
1 2
The most used pharmacological treatment
for pregnant women is selective serotonin
reuptake inhibitors (SSRIs).
3e6 Treatment
with SSRIs during pregnancy in Denmark has
doubled over a short span of time with 1.4%
of pregnancies treated in 2004 compared with
2.4% in 2007. This rapid increase has also
been observed in other countries where the
proportion of pregnant women treated with
an SSRI is reported to be even higher than in
Denmark.
4e8 Several studies have analysed
the consequences of this treatment on preg-
nancy outcomes and indicated an increased
risk of congenital malformations
91 0and
more notably heart defects.
11e21 However, the
data are conﬂicting
11 13 16e18 22e32 and
studies including up to a million pregnancies
indicate little risk of congenital malforma-
tions.
11 16 18 30 31 None of these studies have
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ARTICLE SUMMARY
Article focus
- Relationship between SSRIs and congenital
malformations.
- Focus on malformations of the heart.
- Focus on women with paused treatment during
pregnancy.
Key messages
- Risks of congenital malformations of the heart
are increased for infants whose mothers were
exposed to an SSRI during the ﬁrst trimester.
- Risks of congenital malformations of the heart
are not different for pregnancies exposed during
the ﬁrst trimester as for pregnancies with paused
treatment during pregnancy.
- The found risk increases are moderate in
absolute terms.
Strengths and limitations of this study
- Observational studydno causal relations.
- Nationwide study, including all live births in the
study period.
- Register-based studydno recall bias.
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Open Access Researchsuccessfully managed to differentiate between the
consequences of the drugs themselves and the under-
lying disease. Given the uncertainty of safety and the
common use, we performed a nationwide study of the
relationship between SSRI use and congenital malfor-
mations with focus on congenital heart defects
and comparison with paused use during pregnancy to
account for special characteristics of women using
antidepressants.
MATERIALS AND METHODS
Through the Danish Medical Birth Registry, we identi-
ﬁed all pregnancies in Denmark between 1997 and 2009.
Their drug redemptions were identiﬁed using the
Register of Medicinal Product Statistics. We calculated
the associations between exposure to SSRIs and
congenital malformations using multivariable logistic
regression adjusted for maternal characteristics.
Study population
At birth, all Danish citizens are given a unique perma-
nent identiﬁcation number,
33 which enable personalised
information to be linked across databases. Using the
Danish Medical Birth Registry, we identiﬁed 854008
births between 1997 and 2009. We excluded 5222
records with missing data on date of birth and pregnancy
length. The ﬁnal cohort consisted of 848786 pregnan-
cies (99.4% of all pregnancies). The Danish Medical
Birth Registry includes data on all births in Denmark
since 1973
34 and the following information is contained:
unique identiﬁcation numbers of mother and child as
well recorded time of gestation, which is based on last
menstrual period and ultrasound estimates. We obtained
medical treatment from the Danish Register of Medic-
inal Product Statistics, which, since 1995, has recorded
drugs dispensed from Danish pharmacies. Registration is
close to perfect due to partial reimbursement by
healthcare authorities.
35 For this reason, direct
importing by patients is nearly non-existent. The register
contains type of drug (International Anatomical Thera-
peutic Coding (ATC)), date of redemption, quantity
dispensed and strength.
36 Information on smoking was
gathered from the Danish Medical Birth Registry. Indi-
vidual information on household income and highest
attained level of education was gathered from Statistics
Denmark.
37
Outcome measures
Congenital malformations were identiﬁed through the
Danish National Hospital Register.
38 We identiﬁed chil-
dren with congenital malformation within 1 year of birth
and the corresponding grouping according to the
European Surveillance of Congenital Anomalies
classiﬁcation system guide 1.3.
39
Identiﬁcation of exposure
Exposure to the following SSRIs (ATC codes) was iden-
tiﬁed in the present study: ﬂuoxetine (N06AB03),
citalopram (N06AB04), paroxetine (N06AB05), sertra-
line (N06AB06) and escitalopram (N06AB10). Other
SSRIs were not included because of low incidence of use
(n<50).
SSRI prescriptions redeemed during the study period
were identiﬁed through the Register of Medicinal
Product Statistics. Using the date of prescription,
strength and number of tablets prescribed, we
performed an estimation of exposure periods and
dosages of the individual SSRIs. We calculated dosage as
the average of up to seven prescriptions based on the
standard dose of the individual antidepressant. Calcula-
tion of drug exposure periods using this method has
been described previously.
40
We identiﬁed all pregnancies exposed to an SSRI
during the ﬁrst trimester with a continuous exposure
before pregnancy by deﬁning it as exposure between at
least 1 month before conception and day 84 of preg-
nancy (last day of the ﬁrst trimester). Women changing
exposure to another SSRI during the ﬁrst trimester were
not included in the study (n¼646). In order to address
a possible confounding by indication, we compared our
cohort exposed during the ﬁrst trimester with a control
cohort comprised women with paused exposure during
pregnancy. We deﬁned women with paused exposure as
exposure to an SSRI 3e12 months before conception
and 1e12 months after giving birth but with no expo-
sure to an SSRI between 3 months before conception to
1 month after giving birth. In addition, they had to be
exposed to the same individual SSRI before and after
pregnancy to ensure comparability with women exposed
during the ﬁrst trimester.
We divided the study population into pregnancies
exposed to high or low SSRI dose based on the recom-
mended daily dose values of the individual SSRIs during
pregnancy. Doses over the following cut-off values were
considered as high doses: 20 mg for citalopram, 10 mg
for escitalopram, 20 mg for ﬂuoxetine, 20 mg for
paroxetine and 50 mg for sertraline.
Statistical analysis
Baseline characteristics were compared with c
2 tests for
categorical variables. Risks of malformations were
examined with linear logistic regression models. In
multivariable analyses, we included the mother’s age
divided into ﬁve categories: <20, 20e25, 25e30, 30e35,
>35 years (0% missing values). Annual gross household
income was divided into quartiles (<1% missing values).
The highest obtained level of education attained was
divided into three groups: low, medium and high,
resulting in 4.3% missing values. The number of prior
births (parity), including stillbirths, was divided into
three classes: one, two, and more than two births (<1%
missing values). Year of conception was divided into ﬁve
categories (1995e1997, 1998e2000, 2001e2003,
2004e2006 and 2007e2009). Smoking was divided into
ﬁve categories according to the number of daily ciga-
rette: 0, 1e10, 11e20, >20 and unknown (<1% missing
values). Body mass index (BMI) was divided into four
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SSRIs and the risk of congenital malformationsgroups (<21, 21e25, 26e30, >30). Information on BMI
was only available from 1 January 2004 and includes 7%
missing values in the period 2004e2009 (table 1).
Records with missing values in the above-mentioned
categories were not included in the multivariable analyses.
Ethics
The present study has been approved by the Danish Data
Protection Agency (No. 2008-41-2517). Retrospective
register studies do not require ethical permission in
Denmark. Our ﬁndings are reported according to
strengthening the reporting of observational studies in
epidemiology (STROBE).
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RESULTS
We identiﬁed 4183 pregnancies exposed to an SSRI
throughout the ﬁrst trimester, 806 pregnancies with
paused exposure and 843797 pregnancies not exposed
to an SSRI. Eighty-three per cent of pregnancies exposed
to an SSRI throughout the ﬁrst trimester went on to
redeem, a prescription of an SSRI during the third
trimester. Table 1 shows the basic characteristics for
women exposed to an SSRI and for unexposed women.
Table 2 presents the association between exposure to
SSRIs and major congenital malformation with more
than 10 cases and speciﬁc septal congenital defects of
the heart. For information on risks associated with the
Table 1 Maternal characteristics of women exposed to an SSRI and unexposed
Characteristic
Exposed to SSRIs
Unexposed (n[843797) First trimester (n[4183)
Paused during
pregnancy (n[806)
n (%) n (%) p Value* n (%) p Value*
Education <0.01 <0.001
Short 1731 (41.38) 372 (46.15) 280447 (33.24)
Medium 1119 (26.75) 225 (27.92) 254194 (30.13)
Long 1262 (30.17) 193 (23.95) 272380 (32.28)
Missing values 71 (1.70) 16 (1.99) 36776 (4.36)
Annual household income 0.12 <0.001
<$58335 1320 (31.56) 264 (32.75) 210290 (24.92)
$58335e$93656 1101 (26.32) 222 (27.54) 212110 (25.14)
$93656e$119082 906 (21.66) 185 (22.95) 211436 (25.06)
$119082 or greater 856 (20.46) 135 (16.75) 207247 (24.56)
Missing values 0 ( )0 (  ) 2714 (0.32)
Age (years) <0.001 <0.001
<20 70 (1.67) 20 (2.48) 23324 (2.76)
21e25 555 (13.27) 122 (15.14) 129059 (15.30)
26e30 1364 (32.61) 269 (33.37) 318664 (37.77)
31e35 1423 (34.02) 295 (36.60) 268959 (31.87)
>35 771 (18.43) 100 (12.41) 102791 (12.18)
Missing values 0 ( )0 (  )0 (  )
Parity <0.001 <0.001
1 1983 (47.41) 282 (34.99) 368168 (43.63)
2 1320 (31.56) 310 (38.46) 308992 (36.62)
>2 833 (19.91) 208 (25.81) 162030 (19.20)
Missing values 47 (1.12) 6 (0.74) 4607 (0.55)
Daily cigarettes 0.53 <0.001
0 2810 (67.18) 532 (66) 660888 (78.32)
1e10 1049 (25.08) 211 (26.18) 128269 (15.2)
11e20 66 (1.58) 11 (1.36) 5294 (0.63)
>20 138 (3.30) 34 (4.22) 20967 (2.48)
No information 118 (2.82) 18 (2.23) 27580 (3.27)
Missing values 2 (0.05) 0 ( ) 799 (0.09)
Pre-pregnancy BMI 0.89 <0.001
<21 391 (12.23) 66 (12.60) 53500 (13.95)
21e25 1393 (43.59) 233 (44.47) 186428 (48.62)
26e30 705 (22.06) 117 (22.33) 74673 (19.48)
>30 493 (15.43) 74 (14.12) 41652 (10.86)
Missing values 214 (6.70) 35 (6.68) 27161 (7.08)
Information on pre-pregnancy BMI was only available for women giving birth after 1 January 2004. Thus, this cohort comprises 387142
pregnancies.
*c
2 tests were used to assess the overall p value for the group comparison with pregnancies exposed to an SSRI during the ﬁrst trimester.
BMI, body mass index; SSRI, selective serotonin reuptake inhibitor.
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SSRIs and the risk of congenital malformationsremaining congenital malformations, please refer to
supplement A.
First trimester exposure to any SSRI versus no exposure
The rate of major congenital malformations among
pregnancies exposed to any SSRI throughout the ﬁrst
trimester was 50 per 1000 pregnancies compared with 35
per 1000 unexposed pregnancies (ﬁgure 1). We found
an association between SSRI exposure and major
congenital malformations, adjusted OR 1.33 (95% CI
1.16 to 1.53) (table 2).
When analysing the association between exposure to
any SSRI and the different major malformations
according to the European Surveillance of Congenital
Anomalies classiﬁcation, we found a statistically signiﬁ-
cant association between exposure to an SSRI and
congenital malformations of the heart, adjusted OR 2.01
(95% CI 1.60 to 2.53), and congenital malformations
of the digestive system, adjusted OR 1.80 (95% CI 1.04
to 3.12), but not the remaining major congenital
malformations (table 2).
Paused exposure versus unexposed
The rate of major congenital malformations among
pregnancies with paused exposure during pregnancy was
45 per 1000 pregnancies (ﬁgure 1). The risk of any
major malformation for women with paused exposure to
an SSRI during pregnancy was, adjusted OR 1.27 (95%
CI 0.91 to 1.78), compared with unexposed pregnancies.
When estimating the risk of speciﬁc major congenital
malformations, we found that paused exposure was
associated with congenital malformations of the heart,
adjusted OR 1.85 (95% CI 1.07 to 3.20) (table 2). We
performed additional analyses increasing the drug-free
period before pregnancy to 6 and 9 months and found
similar estimates as for the group pausing exposure
3 months before conception (supplement C).
Other analyses
Exposure to individual SSRIs
We found a signiﬁcant association between major
congenital malformations and exposure to citalopram,
adjusted OR 1.51 (95% CI 1.21 to 1.87), and sertraline,
adjusted OR 1.41 (95% CI 1.03 to 1.92). Furthermore,
we found an association between congenital malforma-
tions of the heart and exposure to citalopram, adjusted
OR 1.91 (95% CI 1.31 to 2.77), ﬂuoxetine, adjusted OR
2.05 (95% CI 1.27 to 3.31), and sertraline, adjusted OR
2.73 (95% CI 1.75 to 4.26). Associations for the
remaining major congenital malformations are
presented in supplement A.
Speciﬁc heart defects
We performed a subanalysis of the speciﬁc congenital
septal defects of the heart and their association with
exposure to SSRIs and found an association between
exposure to any SSRI and septal heart defects, adjusted
OR 2.04 (95% CI 1.53 to 2.72) (table 2). Speciﬁcally,
ventricular septal defects and atrial septal defects were
associated with an increased risk. Increased risk of
congenital septal defects was also found for pregnancies
with paused exposure, adjusted OR 2.56 (95% CI 1.41 to
4.64) (table 2).
For the individual SSRIs, we found an association
between exposure to all SSRIs, except for escitalopram,
and atrial septal defects. Ventricular septal defects was
Table 2 Risk of congenital malformations among women exposed to an SSRI versus women with no exposure
Outcome
Exposed to any SSRI
No exposure
(n[843797) First trimester (n[4183)
Paused during pregnancy
(n[806)
p Value* n (%) OR (95% CI)y n (%) OR (95% CI)y n (%)
Major malformations 208 (4.97) 1.33 (1.16 to 1.53) 36 (4.47) 1.27 (0.91 to 1.78) 0.90 29703 (3.52)
Congenital malformations
of the heart
77 (1.84) 2.01 (1.60 to 2.53) 13 (1.61) 1.85 (1.07 to 3.20) 0.94 7755 (0.92)
Septal defects 49 (1.17) 2.04 (1.53 to 2.72) 11 (1.36) 2.56 (1.41 to 4.64) 0.35 4826 (0.57)
Ventricular septal defects 21 (0.50) 1.62 (1.05 to 2.50) 9 (1.12) 3.74 (1.93 to 7.23) 0.97 2803 (0.33)
Atrial septal defects 34 (0.81) 2.60 (1.84 to 3.68) 6 (0.74) 2.61 (1.17 to 5.84) 0.74 2490 (0.30)
Congenital malformations
of the digestive system
13 (0.31) 1.80 (1.04 to 3.12) 1 (0.12) 0.75 (0.11 to 5.35) 0.59 1545 (0.18)
Congenital malformations
of the internal urinary system
11 (0.26) 0.84 (0.45 to 1.57) ee e 2333 (0.28)
Congenital malformations
of the external genital organs
19 (0.45) 1.55 (0.99 to 2.44) 2 (0.25) 0.89 (0.22 to 3.59) 0.46 2504 (0.30)
Congenital malformations
of the limbs
53 (1.27) 0.93 (0.71 to 1.23) 14 (1.74) 1.37 (0.80 to 2.32) 0.18 11785 (1.40)
Estimates are presented as ORs with 95% CIs.
*p Value for comparison of ORs between pregnancies exposed throughout the ﬁrst trimester and pregnancies with paused exposure during
pregnancy.
yMultivariable logistic regressions are adjusted for mother’s age, parity, income, education, smoking and year of conception.
SSRI, selective serotonin reuptake inhibitor.
4 Jimenez-Solem E, Andersen JT, Petersen M, et al. BMJ Open 2012;2:e001148. doi:10.1136/bmjopen-2012-001148
SSRIs and the risk of congenital malformationsonly associated with exposure to sertraline, adjusted OR
3.60 (95% CI 1.86 to 6.96), and not the remaining
individual SSRIs (supplement A).
Other congenital defects
Studies have reported a possible association between
exposure to an SSRI during pregnancy and omphalo-
cele, anencephaly and craniosynostosis.
9 10 We found an
association for exposure to an SSRI in the ﬁrst trimester
and craniosynostosis (n¼9), adjusted OR 1.94 (95% CI
1.00 to 3.76), but not for omphalocele or anencephaly.
For pregnancies with paused exposure, we found an
association with craniosynostosis (n¼3), adjusted OR
3.64 (95% CI 1.17 to 11.34).
Dosage
We found an adjusted OR for major malformations: OR
1.39 (95% CI 1.14 to 1.68) for low-dose exposure and
1.27 (95% CI 1.03 to 1.56) for high-dose exposure (p for
difference¼0.29).
Fortheindividualmajormalformations,wefoundsimilar
associations for pregnancies exposed to low dose and
pregnancies exposed to high dose, as for the whole cohort
(table 3). Analysing the effect of dose as a continuous
variable yielded no doseeresponse association.
Additional adjustments
In order to identify possible unaccounted confounders,
we performed additional multivariable analyses
including co-medication (psycholeptics; ATC code A05,
and antidiebetics; ATC code A10) as independent vari-
ables in our model. The results showed no considerable
change in the estimates or their level of signiﬁcance
compared with our primary analysis (supplement B).
When including BMI as an independent variable in
our multivariable model, we found the same statistically
signiﬁcant associations for exposure to any SSRI or
individual SSRIs and the speciﬁc congenital malforma-
tions as our multivariable model not adjusted for BMI.
Information on BMI was only available for pregnancies
Figure 1 Rates per 1000
pregnancies of major congenital
malformations for infants exposed
to selective serotonin reuptake
inhibitors in utero. Figure shows
number of infants diagnosed with
a major malformation per 1000
births. Rates are shown with 95%
CIs.
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SSRIs and the risk of congenital malformationsafter 1 January 2004, which reduced our cohort to 3196
pregnancies exposed to an SSRI and 383946 with no
exposure.
Non-SSRI antidepressants
We found no association between congenital malforma-
tions and exposure to non-SSRI antidepressants: tricyclic
antidepressants (ATC N06AA, n¼223) and other antide-
pressants (ATC N06AX, n¼831), adjusted OR 1.04 (95%
CI 0.53 to 2.03) and adjusted OR 0.70 (95% CI 0.47
to 1.05), respectively. We found no associations with
congenital malformations of the heart, adjusted OR
1.33 (95% CI 0.42 to 4.15) for tricyclic antidepressants
and adjusted OR 0.99 (95% CI 0.51 to 1.91) for other
antidepressants.
DISCUSSION
We performed a retrospective nationwide cohort study
analysing the association between redemption of an
SSRI during pregnancy and major congenital malfor-
mations. We found an association between exposure to
an SSRI during the ﬁrst trimester and major congenital
malformations, more speciﬁcally, congenital malforma-
tions of the heart (ventricular septal defects and atrial
septal defects) and congenital malformations of the
digestive system. Furthermore, we found an association
between women with paused SSRI exposure during
pregnancy and congenital malformations of the heart.
Based on ﬁndings described in the published literature,
we will centre the following discussion on major
congenital malformations and congenital malformations
of the heart for pregnancies exposed to SSRIs.
Our study’s results are in accordance with two earlier
Danish studies
20 42 based on cohorts comprising only
part of the entire nation. A third Danish nationwide
study by Pedersen et al
17 found an increased estimate for
major congenital malformations and congenital malfor-
mations of the heart, though not statistically signiﬁcant,
in the studied period 1996e2004. The number of
exposed women in their study was 1370, compared with
ours 4183, which could explain why our estimates
reached statistical signiﬁcance. The study concludes that
there is a class effect of SSRIs on heart defects.
Several studies have not found an association between
exposure to any SSRI and major malformations
overall.
11 13 16 18 22e32 We ﬁnd that some of these study
are not comparable to ours because most of them are
caseecontrol studies and with cohorts much smaller
than ours.
13 22e29 31 Five of the studies are though
similar to ours, based on nationwide cohorts and
national registers, and cohort sizes comparable to ours.
Four are based on Swedish data and are successive
updates
16 18 30 31 and one on Finnish data.
11
The latest update of Swedish data found an increased
risk of cardiovascular congenital malformations for
pregnancies exposed to paroxetine but not for the
remaining individual SSRIs or SSRI as a group.
18 Infor-
mation on SSRI exposure was partly based on antenatal
interviews, which could, although unlikely, give rise to
recall bias. Furthermore, their analyses were adjusted for
BMI. Adjusting our multivariable analysis for BMI had
little effect on the estimates.
The Finnish study found an increased risk of ventric-
ular septal defects for pregnancies exposed to ﬂuoxetine
but not for the remaining individual SSRIs or SSRI as
a group.
11 The study is completely based on national
registers, like our study. Exposure was though deﬁned as
redemption of at least one prescription between 1 month
before pregnancy and the end of the ﬁrst trimester. This
could underestimate the number of exposed women
if prescriptions for an SSRI were redeemed just before
and after this chosen period. This could indicate
continuous exposure during the ﬁrst trimester and push
estimates towards unity and, in theory, explain the lack of
association with major congenital malformations and
speciﬁcally atrial septal defects.
None of the above-mentioned studies assessed the risk
of congenital malformations for women with paused
Table 3 ORs and 95% CIs for association between congenital malformations among women exposed to low-dose and high-
dose SSRI during pregnancy
Outcome
Low-dose SSRI (n[2588) High-dose SSRI (n[1603)
p Valuey n (%) OR (95% CI)* n (%) OR (95% CI)*
Major malformations 121 (4.68) 1.26 (1.05 to 1.51) 87 (5.43) 1.44 (1.15 to 1.79) 0.29
Congenital malformations
of the heart
44 (1.70) 1.83 (1.35 to 2.48) 33 (2.06) 2.26 (1.60 to 3.19) 0.41
Congenital malformations
of the digestive system
8 (0.31) 1.78 (0.89 to 3.58) 5 (0.31) 1.80 (0.75 to 4.35) 0.99
Congenital malformations
of the internal urinary system
6 (0.23) 0.82 (0.37 to 1.83) 5 (0.31) 0.88 (0.33 to 2.34) 0.63
Congenital malformations
of the external genital organs
10 (0.39) 1.32 (0.71 to 2.46) 9 (0.56) 1.91 (0.99 to 3.68) 0.42
Congenital malformations
of the limbs
33 (1.28) 0.94 (0.67 to 1.33) 20 (1.25) 0.91 (0.59 to 1.42) 0.93
*Multivariable logistic regressions are adjusted for mother’s age, parity, income, education, smoking and year of conception.
yp Value for comparison of ORs between pregnancies exposed to low-dose SSRI and high-dose SSRI.
SSRI, selective serotonin reuptake inhibitor.
6 Jimenez-Solem E, Andersen JT, Petersen M, et al. BMJ Open 2012;2:e001148. doi:10.1136/bmjopen-2012-001148
SSRIs and the risk of congenital malformationsexposure during pregnancy and thereby addressing the
possibility of confounding by indication. Furthermore,
neither the Swedish nor the Finnish studies adjusted
their analyses for socioeconomic factors, which in our
study are unevenly distributed between our exposed and
unexposed population. However, additional adjusted
analyses not including socioeconomic factors yielded
estimates and CIs that did not differ from our fully
adjusted analysis (data not shown). Importantly, we
believe that there are socio-demographic differences
between the populations included in these Scandinavian
studies compared with ours. Although Denmark resem-
bles both Sweden and Finland, differences in culture
and healthcare policies could account for the discrep-
ancies in our results. Discrepancies between published
studies could also be due to the low number of cases,
where each case can have a signiﬁcant effect on the
estimate.
Congenital malformations of the heart have
been associated with exposure to SSRIs in some stud-
ies,
10e12 15e18 27 31 42 in contrast to studies not identi-
fying this association.
91 31 92 6Our analyses showed an
increased risk of congenital heart defects for the indi-
vidual SSRIs. Risks of atrial septal defects were further-
more associated with exposure to all individual SSRIs,
except for escitalopram. The lack of statistical signiﬁ-
cance with escitalopram exposure could be due to low
statistical power. We found the same increased risks for
heart defects for those with paused exposure during
pregnancy, which strengthens the assumption of
confounding by indication.
Although statistically signiﬁcant, the increased risks
associated with SSRI exposure are small in absolute
terms. For example, the populations’ background risk of
atrial septal defects is 0.26%, and even if we estimate
a twofold risk increase associated with exposure to any
SSRI, the risk of giving birth to a child with this
congenital malformation would be approximately ﬁve
cases for every 1000 births (ﬁgure 1).
STRENGTHS AND LIMITATIONS
The main weakness is the observational design. We had
access to important covariates but it cannot be excluded
that unaccounted confounder explain the results. Our
study could furthermore be affected by a possible
detection bias. Pregnant women exposed to SSRIs are
reported to have increased rates of observed malforma-
tions due to increased rates of ultrasound examinations
compared with women not treated with SSRIs.
43 In
contrast, detection of a malformation during an ultra-
sound examination could lead to pregnancy termination
and thereby decreased rates of malformations among
the SSRI exposed. On the other hand, infants of women
redeeming prescriptions for SSRIs undergo, in the ﬁrst
year of life, approximately twice as many echocardio-
grams compared with infants of unexposed women.
43
More frequent echocardiograms could increase the risk
of heart defect detection and give rise to information
bias (diagnostic suspicion bias). This bias could partly
explain our ﬁndings. On the other hand, more frequent
echocardiograms could indicate a more severe symp-
tomatology among the exposed children due to an
unaccounted factor.
Importantly, information on indication for elective
termination of pregnancies was not available in our
databases. If pregnant women exposed to an SSRI had
a higher rate of provoked abortions due to severe
malformations, it could mask a possible teratogenic
effect of the drugs.
There is a possibility that we have overestimated SSRI
treatment periods since we cannot adjust for lack of
compliance or the patients’ intention of commencing
a treatment shortly after drug redemption. However, it
has been estimated that the majority of redeemed
prescriptions by pregnant women are taken,
44 and
compliance in Denmark has been estimated to be 80%
for antidepressant treatment during pregnancy.
45
Furthermore, an overestimation of treatment periods
would bias our estimates towards unity. We performed
additional analyses deﬁning exposure as redemption of
two SSRI prescriptions during pregnancy. The results of
these analyses, which are not presented, yielded the
same statistically signiﬁcant association as our primary
analyses. Furthermore, we cannot rule out that women
deﬁned as pausing their treatment 3 months before
conception were misclassiﬁed and had treatment
periods reaching into pregnancy. We addressed this issue
by increasing the washout period before pregnancy and
estimating risks for women pausing treatment 6 and
9 months before conception. The results showed similar
estimates as for women pausing exposure 3 months
before pregnancy (supplement C).
A main strength is the complete national design
including nearly all births in Denmark and the mothers’
drug redemptions in the study period. The Register of
Medicinal Product Statistics includes approximately
97.5% of all redeemed prescriptions.
35 Danish pharma-
cies are, by law, required to register all redeemed
prescriptions as part of the national healthcare reim-
bursement scheme. All prescriptions have been
redeemed and paid for, which increases the probability
of exposure. Recall bias is eliminated since information
was recorded prospectively and not based on question-
naires or interviews. Furthermore, to our knowledge, this
is the ﬁrst study to address a possible confounding by
indication by assessing risks associated with paused
exposure to SSRIs during pregnancy.
Conclusions
Our study shows with high conﬁdence a relationship
between exposure to an SSRI during the ﬁrst trimester
and risk of congenital malformations of the heart. In
addition, we found a nearly identical risk for women who
used an SSRI before and after pregnancy but discon-
tinued use during pregnancy. We ﬁnd both associations
strong enough to conclude that risks related to SSRI use
during the ﬁrst trimester are a result of an unaccounted
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prescription. This was sustained by the lack of relation-
ship between dose and risk. A possible explanation could
be information bias because children of women
redeeming an SSRI are more likely to undergo an
echocardiogram during the ﬁrst year of life. However,
based on our study’s design, we cannot rule out an actual
causal relationship between redemption of an SSRI and
congenital malformations. We found no relationship
with non-SSRI antidepressants, which may indicate
a particular risk with SSRIs, but which may also be
explained by lack of power.
We therefore conclude that the apparent association
between SSRI use and congenital malformations of the
heart may be confounded by indications. The moderate
absolute risk increase combined with uncertainty for
causality still requires the risk versus beneﬁt to be
evaluated in each individual case.
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